Literature DB >> 33424862

NK Cell Interaction With Platelets and Myeloid Cells in the Tumor Milieu.

Stefanie Maurer1, Lucas Ferrari de Andrade2.   

Abstract

Natural killer (NK) cells recognize and kill tumor cells via germ-line encoded receptors and polarized degranulation of cytotoxic molecules, respectively. As such, NK cells help to inhibit the development of cancers. The activating receptor NKG2D induces NK cell-mediated killing of metastasizing tumor cells by recognition of the stress-induced ligands MICA, MICB, and ULBP1-6. However, platelets enable escape from this immune surveillance mechanism by obstructing the interactions between NK cells and tumor cells or by cleaving the stress-induced ligands. It is also being increasingly appreciated that NK cells play additional roles in cancer immunity, including chemokine-mediated recruitment of antigen presenting cells in the tumor microenvironment that is followed by generation of adaptive immunity. However, the NK cell interplays with dendritic cells, and macrophages are extremely complex and involve molecular interactions via NKG2D and cytokine receptors. Specifically, NKG2D-mediated chronic interaction between NK cells and tumor-infiltrating macrophages causes immune suppression by differentiating NK cells toward a dysfunctional state. Here we discuss the underlying mechanisms of NK cell control by platelets and myeloid cells with focus on NKG2D and its ligands, and provide a timely perspective on how to harness these pathways with novel immunotherapeutic approaches.
Copyright © 2020 Maurer and Ferrari de Andrade.

Entities:  

Keywords:  NK cells; NKG2D; myeloid cells; platelets; proteolytic shedding

Year:  2020        PMID: 33424862      PMCID: PMC7785787          DOI: 10.3389/fimmu.2020.608849

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  70 in total

1.  Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.

Authors:  Weiwen Deng; Benjamin G Gowen; Li Zhang; Lin Wang; Stephanie Lau; Alexandre Iannello; Jianfeng Xu; Tihana L Rovis; Na Xiong; David H Raulet
Journal:  Science       Date:  2015-03-05       Impact factor: 47.728

Review 2.  Natural killer cell education and tolerance.

Authors:  Mark T Orr; Lewis L Lanier
Journal:  Cell       Date:  2010-09-17       Impact factor: 41.582

3.  Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.

Authors:  Roberta Castriconi; Claudia Cantoni; Mariella Della Chiesa; Massimo Vitale; Emanuela Marcenaro; Romana Conte; Roberto Biassoni; Cristina Bottino; Lorenzo Moretta; Alessandro Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-19       Impact factor: 11.205

4.  Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection.

Authors:  Takashi Ebihara; Hisayo Masuda; Takashi Akazawa; Masashi Shingai; Hideaki Kikuta; Tadashi Ariga; Misako Matsumoto; Tsukasa Seya
Journal:  Int Immunol       Date:  2007-09-18       Impact factor: 4.823

5.  Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.

Authors:  Guranda Chitadze; Marcus Lettau; Jaydeep Bhat; Daniela Wesch; Alexander Steinle; Daniel Fürst; Joannis Mytilineos; Holger Kalthoff; Ottmar Janssen; Hans-Heinrich Oberg; Dieter Kabelitz
Journal:  Int J Cancer       Date:  2013-04-18       Impact factor: 7.396

6.  Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands.

Authors:  Brett K Kaiser; Daesong Yim; I-Ting Chow; Segundo Gonzalez; Zhenpeng Dai; Henning H Mann; Roland K Strong; Veronika Groh; Thomas Spies
Journal:  Nature       Date:  2007-05-09       Impact factor: 49.962

7.  In vitro and in vivo evidence for shear-induced activation of latent transforming growth factor-beta1.

Authors:  Jasimuddin Ahamed; Nathalie Burg; Keiji Yoshinaga; Christin A Janczak; Daniel B Rifkin; Barry S Coller
Journal:  Blood       Date:  2008-06-10       Impact factor: 22.113

8.  Cancer. Circulating tumor cells.

Authors:  Vicki Plaks; Charlotte D Koopman; Zena Werb
Journal:  Science       Date:  2013-09-13       Impact factor: 47.728

Review 9.  Assessing risk of venous thromboembolism in the patient with cancer.

Authors:  Alok A Khorana; Gregory C Connolly
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  Chronic In Vivo Interaction of Dendritic Cells Expressing the Ligand Rae-1ε with NK Cells Impacts NKG2D Expression and Function.

Authors:  Maelig G Morvan; Marine Champsaur; Boris Reizis; Lewis L Lanier
Journal:  Immunohorizons       Date:  2017-05-01
View more
  4 in total

Review 1.  Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies.

Authors:  Barbara Seliger; Ulrike Koehl
Journal:  Front Immunol       Date:  2022-08-12       Impact factor: 8.786

Review 2.  Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.

Authors:  Cristina Capuano; Chiara Pighi; Simone Battella; Davide De Federicis; Ricciarda Galandrini; Gabriella Palmieri
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

Review 3.  Platelets: The Emerging Clinical Diagnostics and Therapy Selection of Cancer Liquid Biopsies.

Authors:  Yiming Meng; Jing Sun; Yang Zheng; Guirong Zhang; Tao Yu; Haozhe Piao
Journal:  Onco Targets Ther       Date:  2021-05-25       Impact factor: 4.147

Review 4.  The Adverse Impact of Tumor Microenvironment on NK-Cell.

Authors:  Ziming Hu; Xiuxiu Xu; Haiming Wei
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.